The phase 3 IMpassion130 study compared atezolizumab, a monoclonal PD-L1 antibody, plus nab-paclitaxel to placebo plus nab-paclitaxel as first-line treatment for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) [1]. The gene discussed is CD274; the disease is triple-negative breast carcinoma.